Navigation Links
Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
Date:3/11/2008

iew of the short expected survival time of approximately six months in this patient population, it is promising that we have early GBM patients in these trials who have survived past the six-month timeframe, with one patient now surviving 15 months post-treatment."

The open-label Phase I dosing and dosimetry study at U.S. brain cancer centers is enrolling GBM patients with recurrent disease. Patients in this trial receive an initial imaging dose of Cotara before receiving the therapeutic dose. The study's main objectives are to confirm the maximum tolerated dose, to determine radiation dosimetry and to assess overall patient survival, progression-free survival and the proportion of patients alive at six months following Cotara administration. In the three GBM patients enrolled in the first cohort, Cotara was safe and well tolerated, with no dose-limiting toxicities. Patients have been followed post-treatment to determine overall survival, with the first treated patient currently surviving 15 months post-treatment and the last treated patient currently surviving four months post-treatment. Dosimetry analysis indicates that Cotara was concentrated only in the tumor in these patients, and not in other organs.

Mr. King added, "With enrollment of the second patient cohort underway, we welcome Dr. William Shapiro of the Barrow Neurological Institute as principal investigator of our newest dosimetry study clinical site. Dr. Shapiro successfully participated in earlier Cotara studies and we are delighted that his center is now participating in the Cotara dosimetry trial."

"We are pleased to join the dosing and dosimetry trial of Cotara for the treatment of recurrent GBM," said Dr. William Shapiro, director, neuro oncology program; Marley chair, neurology; professor of neurology, University of Arizona College of Medicine; and Cotara principal investigator at the Barrow Neurological Institute. "GBM is a deadly disease with very poor survival prospects for
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
2. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
3. Statement from American Water Works Association on Associated Press Story on Pharmaceuticals in Drinking Water
4. Vion Pharmaceuticals Regains NASDAQ Listing Compliance
5. NPS Pharmaceuticals to Report 2007 Financial Results
6. Trubion Pharmaceuticals Announces Dates for Fourth-Quarter and Year-End 2007 Earnings Conference Call
7. Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results
8. Notice of Bradmer Pharmaceuticals Conference Call
9. Transcept Pharmaceuticals to Present at Cowen and Companys 27th Annual Health Care Conference in Boston
10. ISTA Pharmaceuticals Announces Conference Call and Webcast of Fourth Quarter 2007 Financial Results
11. Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... The Radiology Business Management ... MD, (R-Tex) presenting “What’s Next for Health Care: A View From Capitol Hill” on ... of the Congressional Health Caucus, Rep. Burgess has a special understanding of the real ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... “ Crack’em ... the latest and coolest technology products available to consumers. Amanda Forstrom, a technology expert ... tool helps chefs make less mess while cooking. , Cooking can be a very ...
(Date:7/31/2015)... Louis, MO (PRWEB) , ... July 31, 2015 , ... ... currently underway in U.S. District Court in the Northern District of Illinois, Androgel testosterone ... On Monday, July 20, a docket entry was made recording the minutes of the ...
(Date:7/31/2015)... ... ... Seals Southern Georgia’s Heels & Wheels Duathlon & Triathlon will be held Saturday, August 22nd ... duathlon is a 2 mile run, 13 mile bike ride, and a 3 mile run. ... and a 3 mile run. Heels & Wheels is sponsored by Mayo Clinic System ...
(Date:7/31/2015)... ... July 31, 2015 , ... Intellitec Solutions ... recent implementation of Microsoft Dynamics GP for a senior living facility in Maine. ... supporting senior living communities in 16 states. This further expansion was again a ...
Breaking Medicine News(10 mins):Health News:Congressional Health Caucus Founder Rep. Michael Burgess, MD, to Speak at RBMA Fall Educational Conference 2Health News:Congressional Health Caucus Founder Rep. Michael Burgess, MD, to Speak at RBMA Fall Educational Conference 3Health News:Make Less Mess while Cooking with Crack’em 2Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 2Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 3Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 4Health News:Heels & Wheels for Megan's House Set for Saturday August 22, 2015 in Waycross, Georgia 2Health News:Intellitec Solutions Expands Long term Care ERP Offerings to Maine 2
... ... state of today,s global biopharmaceutical environment. , ... Horsham, PA, USA (Vocus) June 5, 2009 -- ... biopharmaceutical industry,s largest and longest running global, multidisciplinary conference featuring sessions and preconference tutorials ...
... Conference Components , , BUFFALO, N.Y., June 5, ... 2009 Annual Conference will be held June 7-11 at ... This year,s conference will focus on priority public health ... A. , , "The 2009 conference theme, ,Evidence-based ...
... (June 4, 2009) -- For patients with the most common ... protease inhibitor called telaprevir to the current standard therapy can ... it in half the time of standard therapy alone. ... Duke Clinical Research Institute (DCRI) and 36 other sites, including ...
... , WASHINGTON, June 5 The American Society of ... its 2009 Minority Medical Student Award Program (MMSAP), which ... hematology research. Under the program, each award recipient will ... career development mentor, travel stipends to attend the ASH ...
... all patients who undergo myocardial infarction are experiencing onerous fatigue ... fatigued are those who perceive the infarction as a sign ... to control, and those who believe that the illness has ... of a thesis presented at the Sahlgrenska Academy, University of ...
... /PRNewswire-FirstCall/ -- NeoGenomics, Inc. (NASD OTC Bulletin ... the Fifth Annual Noble Financial Equity Conference at 9:15 ... Seminole Hard Rock Hotel in Hollywood, FL. Robert ... give a presentation regarding NeoGenomics, market positioning, financial performance, ...
Cached Medicine News:Health News:DIA 45th Annual Meeting Features Sessions Highlighting Wyeth v. Levine and Pandemic Influenza 2Health News:DIA 45th Annual Meeting Features Sessions Highlighting Wyeth v. Levine and Pandemic Influenza 3Health News:Council of State and Territorial Epidemiologists Annual Conference Begins June 7 in Buffalo, NY 2Health News:Council of State and Territorial Epidemiologists Annual Conference Begins June 7 in Buffalo, NY 3Health News:NEJM study points to new era in hepatitis C treatment 2Health News:NEJM study points to new era in hepatitis C treatment 3Health News:Minority Medical Students Receive Support to Pursue Hematology Research 2Health News:Minority Medical Students Receive Support to Pursue Hematology Research 3Health News:Fatigue common after myocardial infarction 2Health News:NeoGenomics to Present at Noble Financial's 5th Annual Equity Conference on Monday, June 8th 2
(Date:7/31/2015)... 31, 2015 Egalet Corporation (Nasdaq: ... company focused on developing, manufacturing and marketing innovative ... previously announced underwritten public offering of 7,666,667 shares ... price of $11.25 per share. The shares of ... issued upon the exercise in full by the ...
(Date:7/31/2015)... , July 31, 2015 According ... Market by Product (Bioimpedance Analyzers (BIA), Dual-Energy X-ray Absorptiometry ... Weighing) - Global Analysis & Forecast to 2019", published ... pegged at $911.1 Million 2014 and is estimated to ... CAGR of 9.4% from 2014 to 2019. ...
(Date:7/30/2015)... SAN DIEGO , July 30, 2015 ... announced it has signed a definitive agreement ... provider of non-invasive ventilation and sleep-disordered breathing ... strong clinical, innovation and market reputation in China, combined with ResMed,s global leadership ... of people in China ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3
... Japan, June 23 Although previous studies,suggest that ... of the eye in children with progressing myopia, ... Using a rigorous study design,and precise optical measuring ... Madrid are undertaking the Myopia Control with,Orthokeratology contact ...
... According to new data from,PAREXEL International Corporation (Nasdaq: ... the number of new,industry-sponsored clinical trial initiations, or ... in 2007. PAREXEL,s analysis shows that the,biopharmaceutical industry ... support of new clinical studies for drugs in,2007, ...
Cached Medicine Technology:Menicon Undertakes With the Novovision Clinic a Paediatric Myopia Control Clinical Trial 2PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated 2PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated 3PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated 4PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated 5
... of minor knee pain like arthritis, tendonitis ... with the motion of the knee, applying ... tendon and assisting in the relief of ... with high density foam padding molds itself ...
... Bariatric Knee Immobilizer is made of lightweight ... a breathable foam material that wicks moisture ... posterior aspect of the splint is uniquely ... The loop and lock closure straps allow ...
... brushed nylon, laminated to breathable foam. Three ... strap. Velcro straps with loop closures. Lightweight ... lateral stays., ,Available with optional hot ... Pad helps defeat the pain cycle by ...
... supports are a convenient, reusable, patient-friendly ... for common orthopedic conditions/instabilities. These products ... compression and lateral to medial influence ... the skin and soft tissue structures. ...
Medicine Products: